These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32500362)

  • 1. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.
    Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R
    MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties.
    Hu S; Datta-Mannan A; D'Argenio DZ
    AAPS J; 2022 Dec; 25(1):5. PubMed ID: 36456779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.
    Zheng Y; Tesar DB; Benincosa L; Birnböck H; Boswell CA; Bumbaca D; Cowan KJ; Danilenko DM; Daugherty AL; Fielder PJ; Grimm HP; Joshi A; Justies N; Kolaitis G; Lewin-Koh N; Li J; McVay S; O'Mahony J; Otteneder M; Pantze M; Putnam WS; Qiu ZJ; Ruppel J; Singer T; Stauch O; Theil FP; Visich J; Yang J; Ying Y; Khawli LA; Richter WF
    MAbs; 2012; 4(2):243-55. PubMed ID: 22453096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling.
    Kumar M; Lanke S; Yadav A; Ette M; Mager DE; Shah DK
    Antibodies (Basel); 2024 Jul; 13(3):. PubMed ID: 39051330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
    Glassman PM; Chen Y; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
    Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
    AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A translational platform PBPK model for antibody disposition in the brain.
    Chang HY; Wu S; Meno-Tetang G; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
    Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
    MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.
    Zhao L; Ji P; Li Z; Roy P; Sahajwalla CG
    J Clin Pharmacol; 2013 Mar; 53(3):314-25. PubMed ID: 23426855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.
    Davda JP; Dodds MG; Gibbs MA; Wisdom W; Gibbs J
    MAbs; 2014; 6(4):1094-102. PubMed ID: 24837591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties.
    Hu S; Datta-Mannan A; D'Argenio DZ
    MAbs; 2022; 14(1):2056944. PubMed ID: 35491902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiscale pharmacokinetic modeling of systemic exposure of subcutaneously injected biotherapeutics.
    Zheng F; Hou P; Corpstein CD; Park K; Li T
    J Control Release; 2021 Sep; 337():407-416. PubMed ID: 34324897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.